Bullish
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA Feedback - What's Changed
Ocular Therapeutix (OCUL) shares increased by 8.2% following positive Week 52 data from its Phase 3 SOL-1 trial for AXPAXLI, showing superior durabili...